 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...2223242526272829303132...4142» |
- Arimidex (anastrozole) / AstraZeneca, Remedica
A Case of Paraneoplastic Cerebellar Degeneration Secondary to Breast cancer: Barriers to intensive rehabilitation () - Feb 11, 2020 - Abstract #ISPRM2020ISPRM_335;
Patient received IVIG, plasma exchange, right modified mastectomy and started hormonal therapy with anastrozole...In addition to demonstrating functional improvements, this case report highlights important and underestimated barriers to rehabilitation in patients with PCD. Rehab treatment plan should include early evaluation and treatment of mood disturbances as well as symptomatic management of neurologic sequela in patients with PCD in efforts to optimize time in acute rehabilitation and decrease length of stay.
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Enrollment change, PD(L)-1 Biomarker, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 10, 2020
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Rehab treatment plan should include early evaluation and treatment of mood disturbances as well as symptomatic management of neurologic sequela in patients with PCD in efforts to optimize time in acute rehabilitation and decrease length of stay. Recruiting --> Active, not recruiting | N=56 --> 30
- | Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (clinicaltrials.gov) - Feb 10, 2020
P1/2, N=36, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Active, not recruiting | N=56 --> 30 Trial completion date: Nov 2020 --> Jul 2022 | Trial primary completion date: Nov 2019 --> Jul 2021
- Anthropometric and Reproductive Outcomes of Patients with Gonadotropin-Independent Precocious Puberty Due to McCune-Albright Syndrome After Treatment with Distinct Therapeutic Agents (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2478;
All patients were treated with one or more of the following agents: tamoxifen, medroxyprogesterone acetate, aromatase inhibitors (anastrozole or letrozole) and anti-androgens (cyproterone), and, in cases with secondary gonadotropic axis activation, depot GnRHa was used...Tamoxifen plus medroxyprogesterone, or cyproterone, or leuprorelin were used (each one) as the first choice in 1 patient (7.6%)...Despite a reasonable number of treatment options for peripheral PP in MAS, none of them showed proven effective results in stopping vaginal bleeding, reduce pubertal progression and preserving potential genetic adult height. Therefore, due to the extremely heterogeneous nature of PPP of MAS, the clinical treatment remains a challenge.
- Decadron (dexamethasone) / Merck (MSD)
Rare Case of Adrenocortical Carcinoma with Tumor Extension into the Inferior Venacava, Right Atrium and Right Ventricle. (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2069;
Complete tumor resection is the only curative approach with adjuvant therapies aiming to decrease the risk of recurrence only. Due to the aggressive nature of the tumor and quick development of metastasis, early diagnosis gives the best chance of resection and hence the greatest chances of survival.
- Arimidex (anastrozole) / AstraZeneca, Remedica, Eligard (leuprolide acetate) / TOLMAR, Astellas, Sanofi
Gain in Near Adult Height Using the Combination of an LHRH Analogue and an Aromatase Inhibitor in Early Maturing Girls with Compromised Growth. The “Gail” Study ISRCTN11469487 (Room 11) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2006;
As a result, the combination therapy continued with anastrozole monotherapy, ends in the shortest distance from target height. This implies that the addition of the anastrozole to an LHRHa apart from being safe, is effective in ameliorating substantially Near Adult Height making the intervention meaningful.
- methimazole / Generic mfg., simvastatin / Generic mfg., paclitaxel / Generic mfg.
The First Case Report of Delayed Onset Methimazole Induced Pancreatitis (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1878;
Bradley W. Devrieze, MD Clinical case a 75-year-old Caucasian female with a past medical history of invasive ductal carcinoma of the right breast managed with mastectomy and Taxol based chemotherapy completed seven months ago and maintained on Trastazumab and Anastrozole, dyslipidemia, subclinical hyperthyroidism with multinodular goiter on MMI 7.5 mg daily for the last 4 years...She had a previous episode of an acute pancreatitis 7 months ago which was believed to be secondary to simvastatin, which was stopped at that time...To our knowledge this is the first case report of a delayed-onset pancreatitis induced by MMI. Abbreviations : Methimazole (MMI) Laboratory Values: Lipase : (73 – 393) U/L Triglyceride <149 mg/dl Calcium : (8.5 - 10.5) mg/dl TSH : (0.4 - 3.8) UIU/ml Total T3 : (50 – 170) ng/dl T4 free : (0.7 - 1.4) ng/dl
- | Trial completion date, Trial primary completion date, Surgery: Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery (clinicaltrials.gov) - Feb 7, 2020
P3, N=3697, Active, not recruiting, Sponsor: Gruppo Italiano Mammella (GIM)
Abbreviations : Methimazole (MMI) Laboratory Values: Lipase : (73 – 393) U/L Triglyceride <149 mg/dl Calcium : (8.5 - 10.5) mg/dl TSH : (0.4 - 3.8) UIU/ml Total T3 : (50 – 170) ng/dl T4 free : (0.7 - 1.4) ng/dl Trial completion date: Jul 2018 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2020
- | New trial, Metastases: Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy (clinicaltrials.gov) - Feb 6, 2020
P, N=760, Completed, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | anastrozole / Generic mfg., everolimus / Generic mfg., fulvestrant / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer (clinicaltrials.gov) - Feb 5, 2020
P3, N=37, Terminated, Sponsor: Southwest Oncology Group
Trial completion date: Jul 2018 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2020 N=825 --> 37 | Trial completion date: May 2022 --> Dec 2019 | Suspended --> Terminated | Trial primary completion date: May 2022 --> Dec 2019; lack of accrual
- | fulvestrant / Generic mfg.
New P2 trial: Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (clinicaltrials.gov) - Feb 4, 2020
P2, N=124, Recruiting, Sponsor: M.D. Anderson Cancer Center
- || Arimidex (anastrozole) / AstraZeneca, Remedica, Ilaxten (bilastine) / Otsuka
Clinical, Journal: Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. (Pubmed Central) - Jan 30, 2020
This analysis has identified a significant continuing reduction in breast cancer with anastrozole in the post-treatment follow-up period, with no evidence of new late side-effects. Further follow-up is needed to assess the effect on breast cancer mortality.
- | Retrospective data, Journal, HEOR: Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis. (Pubmed Central) - Jan 30, 2020
Further follow-up is needed to assess the effect on breast cancer mortality. The findings of this study will be published in a peer-reviewed journal.
- || Arimidex (anastrozole) / AstraZeneca, Remedica, fluconazole / Generic mfg.
Clinical, Journal: Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report. (Pubmed Central) - Jan 30, 2020
This case of pulmonary cryptococcosis may have been induced by a decrease in estrogen level caused by the aromatase inhibitor, anastrozole. Treatment of pulmonary cryptococcosis with concurrent anastrozole use may be ineffective, and it may be better to discontinue the aromatase inhibitor.
- | anastrozole / Generic mfg.
Trial completion: Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) (clinicaltrials.gov) - Jan 30, 2020
P4, N=23, Completed, Sponsor: Baylor College of Medicine
Treatment of pulmonary cryptococcosis with concurrent anastrozole use may be ineffective, and it may be better to discontinue the aromatase inhibitor. Recruiting --> Completed
- || Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: Radiation Therapy without Endocrine Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation. (Pubmed Central) - Jan 28, 2020
Recruiting --> Completed Women age 70 or above with low-risk early breast cancer who are reluctant or unable to pursue adjuvant aromatase inhibition can safely pursue adjuvant radiation alone, with limited differences in outcome and a modest increase in costs.
- ||| Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal, Adverse events: Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events. (Pubmed Central) - Jan 24, 2020
Our patient's drug reaction occurred 2 months after starting the anastrozole and improved after a course of oral and topical corticosteroids. She was able to be switched to an alternate aromatase inhibitor without a recurrence of her adverse skin reaction.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. (clinicaltrials.gov) - Jan 22, 2020
P2, N=37, Not yet recruiting, Sponsor: Ruijin Hospital
- || Imlygic (talimogene laherparepvec) / Amgen
Enrollment open: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - Jan 22, 2020
P1b, N=25, Recruiting, Sponsor: University of California, San Francisco
She was able to be switched to an alternate aromatase inhibitor without a recurrence of her adverse skin reaction. Not yet recruiting --> Recruiting
- || Arimidex (anastrozole) / AstraZeneca, Remedica, Tamoxis (tamoxifen) / Bioprofarma
Clinical, Journal: Assessment and Management of Bone Health in Women with Early Breast Cancer Receiving Endocrine Treatment in the DATA Study. (Pubmed Central) - Jan 16, 2020
In conclusion, extended anastrozole therapy was not associated with a higher incidence of osteoporosis. Anastrozole-use was associated with a BMD decrease; however, the decline was modest and partially reversible after anastrozole cessation.
- | Avastin (bevacizumab) / Roche
Trial primary completion date: Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance (clinicaltrials.gov) - Jan 13, 2020
P1, N=277, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Anastrozole-use was associated with a BMD decrease; however, the decline was modest and partially reversible after anastrozole cessation. Trial primary completion date: Sep 2019 --> Sep 2020
- | NN1213 / Novo Nordisk
Trial primary completion date: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov) - Jan 13, 2020
P2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Sep 2019 --> Sep 2020 Trial primary completion date: Dec 2019 --> Jun 2020
- | Faslodex (fulvestrant) / AstraZeneca
Retrospective data, Review, Journal: Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis. (Pubmed Central) - Jan 11, 2020
Trial primary completion date: Dec 2019 --> Jun 2020 Within the limitations of this network meta-analysis, the comparison indicates that CDK4/6is plus AIs might represent a better option for HR+ ABC as a first-line endocrine treatment compared with fulvestrant.
- | Arimidex (anastrozole) / AstraZeneca, Remedica, Tamoxis (tamoxifen) / Bioprofarma
Preclinical, Journal: Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro. (Pubmed Central) - Jan 8, 2020
Hormone-therapy augments tumour cell-induced platelet activation, which may be linked to cell phenotype. This may have clinical implications for treatment strategies.
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy (clinicaltrials.gov) - Jan 7, 2020
P=N/A, N=15, Completed, Sponsor: University of Washington
This may have clinical implications for treatment strategies. Active, not recruiting --> Completed
- || Arimidex (anastrozole) / AstraZeneca, Remedica
Anastrozole Maintains #BreastCancer Prevention Effect in Long-Term Follow-Up #bcsm #SABCS2019 #SABCS19 https://t.co/LFG4oVxly1 (Twitter) - Dec 30, 2019
- | Retrospective data, Review, Journal: Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer. (Pubmed Central) - Dec 23, 2019
Based on the derived STE, it is possible to draw conclusions on a significant effect in OS for a hypothetical trial demonstrating an upper confidence limit of HR < 0.60 in PFS. However, only final OS results are able to confirm if a clinical relevant difference in survival time can be achieved.
- ||| Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
Clinical, P3 data, Journal: Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. (Pubmed Central) - Dec 23, 2019
P3
The GEICAM/2006-10 study did not show a statistically significant increase in DFS by adding adjuvant F to A, though no firm conclusions can be drawn because of the limited sample size due to the early stop of the trial. ClinicalTrials.gov: NCT00543127.
- || Arimidex (anastrozole) / AstraZeneca, Remedica
PK/PD data, Journal: Development of an intravaginal ring delivering simultaneously anastrozole and levonorgestrel: a pharmacokinetic perspective. (Pubmed Central) - Dec 20, 2019
The PK characteristics successfully guided the design of clinical studies investigating the drug-drug interaction (DDI) potential. No relevant DDI between both the investigated or other vaginally administered drugs were identified.
- ||| Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Metastases: MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) - Dec 17, 2019
P3, N=463, Active, not recruiting, Sponsor: Eli Lilly and Company
No relevant DDI between both the investigated or other vaginally administered drugs were identified. Trial completion date: Nov 2019 --> Nov 2020
- |||| Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical: Years after end of treatment, women at high risk of #breastcancer who were on anastrozole preventive therapy continued to be protected better, reported Jack Cuzick, PhD, of the Wolfson Institute of @QMUL, at #SABCS19. @SABCSSanAntonio #BCSM @EdithPerezMD https://t.co/vX5aV02NYO (Twitter) - Dec 14, 2019
- ||||| Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical: Anastrozole for women with high risk: -⬇️ breast cancer by 49%, mostly in ER+ -36% reduction seen post treatment period -NNT=29 to prevent 1 breast cancer -No change in breast cancer or overall mortality #bcsm #SABCS19 (Twitter) - Dec 12, 2019
- ||||| Arimidex (anastrozole) / AstraZeneca, Remedica, Ilaxten (bilastine) / Otsuka
Clinical, Adverse events: “No real adverse events seen with 5y anastrozole versus placebo” in IBIS II trial. Very reassuring to see no signal for fracture or cardiac disease. Supports incredible safety of AI therapy! #SABCS19 (Twitter) - Dec 12, 2019
- ||| Arimidex (anastrozole) / AstraZeneca, Remedica, Ilaxten (bilastine) / Otsuka
Ibis II prevention study with anastrozole. Long term outcomes. NNT=29 to prevent 1 tumor. (Twitter) - Dec 12, 2019
- || camizestrant (AZD9833) / AstraZeneca
Trial completion date, Trial primary completion date: SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) - Dec 11, 2019
P1, N=168, Recruiting, Sponsor: AstraZeneca
Trial completion date: Nov 2019 --> Nov 2020 Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Oct 2020 --> Mar 2021
- | Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
Preclinical, Journal, IO Biomarker: The role of androgens on periodontal repair in female rats. (Pubmed Central) - Nov 30, 2019
Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Oct 2020 --> Mar 2021 The blockage of androgen receptors significantly impair bone repair in females through mechanisms that are different from those related to estrogen receptors.
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Journal: The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. (Pubmed Central) - Nov 30, 2019
The blockage of androgen receptors significantly impair bone repair in females through mechanisms that are different from those related to estrogen receptors. Parity laws had a modest effect on lowering the cost of anastrozole and exemestane, but more focused efforts to limit out-of-pocket costs for endocrine therapy may have a greater impact on medication adherence.
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Preclinical, Journal: A novel GC-MS methodology to evaluate aromatase activity in human placental microsomes: a comparative study with the standard radiometric assay. (Pubmed Central) - Nov 29, 2019
In addition, it may be applied for the evaluation of the anti-aromatase activity of new potential AIs. Graphical abstract.
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - Nov 27, 2019
P2, N=40, Recruiting, Sponsor: Antoinette Tan, MD
Graphical abstract. Trial primary completion date: Oct 2019 --> Mar 2020
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Preclinical, Journal: Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos. (Pubmed Central) - Nov 27, 2019
Among these complexes, [Ru(η-CH)(PPh)(η-ATZ)Cl]BPh (3) was found to be the most stable in cell culture media, to lead to the highest cellular uptake and in vitro cytotoxicity in two ER+ human breast cancer cell lines (MCF7 and T47D), and to induce a decrease in aromatase activity in H295R cells. Exposure of zebrafish embryos to complex 3 (12.5 μM) did not lead to noticeable signs of toxicity over 96 h, making it a suitable candidate for further in vivo investigations.
- | Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
Journal: Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase-estrogen receptor axis. (Pubmed Central) - Nov 22, 2019
Moreover, immunological investigation further revealed that targeting the whole CYP19A1-ESR axis might cause the inactivation of anti-tumor immune response, which largely attenuated its application prospects in breast cancer. Considered the pathophysiologic functions of CYP19A1 and ESR1/ESR2-mediated signaling pathway in breast cancer seem as more complicated than what we have already known, more precise evaluation will be needed in urgent.
- Arimidex (anastrozole) / AstraZeneca, Remedica, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
A CASE OF INTRAVENTRICULAR THROMBUS AFTER SIMULTANEOUS SURGERY FOR LEFT LUNG CANCER AND RIGHT BREAST CANCER () - Nov 21, 2019 - Abstract #APSR2019APSR_538;
After irradiation of preserved breast tissue, anastrozole and UFT were administered as adjuvant therapies for breast cancer and lung cancer, respectively...Administration of dabigatran etexilate was started...Thrombus diameter subsequently tended to shrink slowly. Currently, 80 weeks after thrombus turns out, administration of heparin calcium is being continued with strict follow-up observation.
- ||||| Opdivo (nivolumab) / BMS
New P2 trial: A Study of Neoadjuvant Nivolumab + Abemaciclib or Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer (EUDRACT) - Nov 19, 2019
P2, N=324, Ongoing, Sponsor: Bristol-Myers Squibb International Corporation
- everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Nov 15, 2019
P2, N=3, Active, not recruiting, Sponsor: Emory University
Currently, 80 weeks after thrombus turns out, administration of heparin calcium is being continued with strict follow-up observation. Trial completion date: Oct 2020 --> Nov 2021 | Trial primary completion date: Oct 2019 --> Nov 2020
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Combination therapy: Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer (clinicaltrials.gov) - Nov 15, 2019
P2, N=160, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Oct 2020 --> Nov 2021 | Trial primary completion date: Oct 2019 --> Nov 2020 Trial completion date: Jun 2019 --> May 2020
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Nov 15, 2019
P2, N=56, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jun 2019 --> May 2020 Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2021
- || Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: Effects of testosterone and 17β-estradiol on osteogenic and adipogenic differentiation capacity of human bone-derived mesenchymal stromal cells of postmenopausal women. (Pubmed Central) - Nov 14, 2019
These effects were abrogated by the aromatase inhibitor anastrozole...In conclusion, aromatase activity is limited to differentiated hMSCs and the resulting 17β-estradiol enhances late osteogenic differentiation stages via ERα. Adipogenic differentiation, on the other hand, is reduced by both sex steroids: testosterone via AR and 17β-estradiol.
- | Verzenio (abemaciclib) / Eli Lilly
New P3 trial, Metastases: AMBRE: Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (clinicaltrials.gov) - Nov 14, 2019
P3, N=378, Not yet recruiting, Sponsor: UNICANCER
- Arimidex (anastrozole) / AstraZeneca, Remedica
ESTROGEN-DEPENDENT ANGIOEDEMA RESPONSIVE TO ANASTROZOLE IN A MALE WITH FAMILIAL HYPERESTROGENEMIA AND HEREDITARY CANCER RISK (Monitor 3) - Nov 9, 2019 - Abstract #ACAAI2019ACAAI_698;
Given the patient’s family history, hyperestrogenemia worsened with testosterone therapy, and a favorable response to anastrozole therapy, we postulate the presence of a CYP19A1 gain of function mutation leading to estrogen-dependent cancers and angioedema. Patients family history with relevant conditions and inheritance.